| 词条 | Aurobindo Pharma |
| 释义 |
| name = Aurobindo Pharma Limited | logo = Aurobindo_Pharma_logo.png | logo_size = | logo_alt = | logo_caption = | logo_padding = | image = | image_size = | image_alt = | image_caption = | native_name = | native_name_lang = | romanized_name = | former_name = | type = Public | traded_as = {{NSE|AUROPHARMA }} {{BSE|524804}} | ISIN = | industry = Pharmaceuticals | fate = | predecessor = | successor = | founded = 1986 | founder = | defunct = | hq_location = Hyderabad, Telangana, India | hq_location_city = | hq_location_country = | num_locations = | num_locations_year = | area_served = dient Organic Intermediates | brands = | production = | production_year = | services = | revenue = {{Increase}} {{INRConvert|136.50|b}}[1] | revenue_year = 2017 | operating_income = | income_year = | net_income = {{Increase}} {{INRConvert|19.780|b}}[2] | net_income_year = 2017 | aum = | assets = | assets_year = | equity = | equity_year = | owner = | members = | members_year = | num_employees = 16000[3] | num_employees_year = March 2017 | parent = | divisions = | subsid = | module = | ratio = | rating = | footnotes = | website = {{URL|http://www.aurobindo.com/}} }}Aurobindo Pharma Limited is a pharmaceutical manufacturing company headquartered in HITEC City, Hyderabad, India. The company manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company’s area of activity includes six major therapeutic/product areas: antibiotics, anti-retrovirals, cardiovascular products, central nervous system products, gastroenterologicals, and anti-allergics.{{citation needed|date=December 2011}} The company markets these products in over 125 countries.{{citation needed|date=December 2011}} Its marketing partners include AstraZeneca[4] and Pfizer.[5] CompanyThe company commenced operations in 1988-89 with a single unit manufacturing semi-synthetic penicillin (SSP) in Puducherry. Aurobindo Pharma became a public company in 1992 and listed its shares in the Indian stock exchanges in 1995. Aurobindo Pharma also has a presence in key therapeutic segments such as neurosciences, cardiovascular, anti-retrovirals, anti-diabetics, gastroenterology and cephalosporins, among others. Aurobindo Pharma features among the top 10 companies in India in terms of consolidated revenues.{{citation needed|date=September 2012}} Aurobindo exports to over 125 countries across the globe with more than 70% of its revenues derived out of international operations. In 2014, Aurobindo purchased the generic operations of Actavis in 7 Western European countries for $41 million.[6][7] Business expansionAurobindo Pharma plans to expand its product portfolio with high value products in oncology, hormones, biosimilars and novel drug delivery solutions like depot injections, inhalers, patches and films. It has also set its sights on geographic expansion in new territories like Poland, Italy, Spain, Czech Republic, Portugal and France as generic penetration in these countries is low.[8] In 2017, Aurobindo Pharma inked a pact to acquire Portugal’s Generis Farmaceutica SA from Magnum Capital Partners for a consideration of €135 million.[9] It also acquired four biosimilar products from Swiss firm TL Biopharmaceutical AG.[10] Aurobindo Pharma Ltd. signed a definitive agreement to purchase the Apotex businesses in Poland, the Czech Republic, the Netherlands, Spain and Belgium. The agreement is conditional on the receipt of competition clearances for the transaction by the Dutch and Polish authorities. As part of the proposed sale, Apotex will enter into a transitional manufacturing and supply arrangement with Aurobindo to support the ongoing growth plans of these businesses.[11] Legal issuesIn December 2016, the attorneys general of 20 states filed a civil complaint accusing Aurobindo Pharma of a coordinated scheme to artificially maintain high prices for a generic antibiotic and diabetes drug. The complaint alleged price collusion schemes between six pharmaceutical firms including informal gatherings, telephone calls, and text messages.[12] On 11 April 2018, Aurobindo was featured in the Dutch documentary television program Zembla.[13] It details accusations against the company of both environmental damage and poor working conditions for their employees in Hyderabad, India. RecallsIn 2018[14] and 2019[15], Aurobindo Pharma USA recalled tablets containing valsartan due to the detection of N-Nitrosodiethylamine (NDEA) which is a probable human carcinogen. See also
References1. ^http://www.aurobindo.com/investor-relations/finance/financial-highlights 2. ^http://www.aurobindo.com/investor-relations/finance/financial-highlights 3. ^http://www.aurobindo.com/docs/annual-reports/aurobindo-ar-2016-17.pdf 4. ^"Aurobindo Pharma signs supply pact with AstraZeneca", Economic Times, 6 September 2010 5. ^"Pfizer, Astra deals to drive Aurobindo Pharma’s growth", Economic Times, 5 November 2010 6. ^{{cite news | type=paper | date=15 February 2014 | volume=34 | issue=4 | page=10 | work=Gen. Eng. Biotechnol. News | title=Aurobindo Buys Actavis' European Operations | department=News: Industry Watch }} 7. ^{{cite news|url=http://www.btvin.com/videos/watch/5197/aurobindo-to-buyout-actavis'-eu-ops|title=Aurobindo To Buyout Actavis' EU Ops|accessdate=20 January 2014| publisher=Bloomberg TV India}} 8. ^{{cite news | url=https://www.thehindubusinessline.com/companies/aurobindo-pharma-to-focus-on-highvalue-products-in-us/article9722248.ece | title=Aurobindo Pharma to focus on high-value products in US | date=12 January 2018 | newspaper=The Hindu Business Line | first=G Naga | last=Sridhar | accessdate=6 January 2019}} 9. ^http://www.livemint.com/Companies/lv3KqcJ8s1e5hn68BKyfEO/Aurobindo-Pharma-to-acquire-Portugals-Generis-for-135-mill.html 10. ^http://www.livemint.com/Companies/HeABAdTWeZEUHYDmNMxzcJ/Aurobindo-Pharma-buys-4-biosimilar-products-from-TL-Biopharm.html 11. ^https://www.prnewswire.com/news-releases/aurobindo-signs-a-definitive-agreement-to-acquire-apotex-businesses-in-poland-czech-republic-the-netherlands-spain-and-belgium-808992512.html 12. ^{{cite news |last=Thomas |first=Katie |url=https://www.nytimes.com/2016/12/15/business/generic-drug-price-lawsuit-teva-mylan.html |title=20 States Accuse Generic Drug Companies of Price Fixing |work=The New York Times |date=2016-12-15 |accessdate=2016-12-16 }} 13. ^https://zembla.bnnvara.nl/nieuws/manufacturer-of-dutch-medicines-exploit-workers-and-pollute-the-environment 14. ^{{cite web |title=Aurobindo Pharma USA, Inc. Initiates Voluntary Nationwide Consumer Level Recall of 80 Lots of Amlodipine Valsartan Tablets USP, Valsartan HCTZ Tablets, USP and Valsartan Tablets USP, Due to the Detection of NDEA (N-Nitrosodiethylamine) Impurity |url=https://www.fda.gov/Safety/Recalls/ucm629213.htm |year=2018 |quote=Aurobindo Pharma USA, Inc. is conducting a voluntary recall of 80 lots of Amlodipine Valsartan Tablets USP, Valsartan HCTZ Tablets, USP and Valsartan Tablets USP to the consumer level due to the detection of trace amounts of an unexpected impurity found in the finished drug product. The impurity detected in the finished drug product is N-nitrosodiethylamine (NDEA), which is a substance that occurs naturally in certain foods, drinking water, air pollution, and industrial processes, and has been classified as a probable human carcinogen as per International Agency for Research on Cancer (IARC) classification.}} 15. ^{{cite web |title=AurobindoPharma USA, Inc. Initiates a Voluntary Nationwide Consumer Level Recall Expansion of 38 Lots of Amlodipine Valsartan Tablets USP and Valsartan Tablets, USP due to the detection of NDEA (N-Nitrosodiethylamine) Impurity |url=https://www.fda.gov/Safety/Recalls/ucm632442.htm |year=2019 |quote=AurobindoPharma USA, Inc. and Acetris Health LLC. Are conducting a voluntary recall expansion of 39 lots of Valsartan and Amlodipine and Valsartan tablets to the consumer level due to the detection of trace amounts of an unexpected impurity found in the finished drug product. This recall is an expansion of the recall initiated 12/31/18 The impurity detected in the finished drug product is N-nitrosodiethylamine (NDEA), which is a substance that occurs naturally in certain foods, drinking water, air pollution, and industrial processes, and has been classified as a probable human carcinogen as per International Agency for Research on Cancer (IARC) classification.}} External links
5 : Pharmaceutical companies of India|Companies listed on the National Stock Exchange of India|Companies listed on the Bombay Stock Exchange|Companies based in Hyderabad, India|Indian brands |
| 随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。